Category
Diseases
Disease-area coverage across oncology, infectious disease, rare conditions, metabolic and cardiovascular disease and more — focused on the evidence, the treatments and the access questions in each.
546 articles in this topic.
Articles in this category
10/23/2026
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess
Read Article →
10/23/2026
FDA Launches Neuroscience Medical Product Development Program
The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess
Read Article →
10/23/2026
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal
Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.
Read Article →
10/21/2026
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Two post hoc REDEFINE 1 analyses show CagriSema weight loss in women held across premenopausal, perimenopausal and postmenopausal stages. #SyenzaNews #obesity #MarketAccess
Read Article →
10/20/2026
Biomarker laboratory in Portugal opens at University of Porto
A new biomarker laboratory in Portugal opens on 21 October at the University of Porto, funded with 2.1 million euros from the PRR. #SyenzaNews #biomarkers #precisionmedicine
Read Article →
10/20/2026
Emvistegrast in ulcerative colitis hits Phase 2 primary endpoint
Gilead's once-daily oral emvistegrast met the primary endpoint in Phase 2 SWIFT ulcerative colitis data, with 66% clinical response at Week 12 versus 37% on placebo. #SyenzaNews #biotechnology #MarketAccess
Read Article →
10/20/2026
Jemperli rectal cancer approval may let some patients skip standard treatment
FDA grants accelerated approval for Jemperli in locally advanced rectal cancer, based on interim AZUR-1 results. #SyenzaNews #oncology #MarketAccess
Read Article →
10/19/2026
Adverse reaction reports in Portugal rise with GLP-1 use
Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.
Read Article →
10/19/2026
Foundayo Oral GLP-1 Tablet Gets Positive EU Opinion
The EMA's CHMP has backed Foundayo, a once-daily orforglipron tablet, for weight management and type 2 diabetes.
Read Article →
10/19/2026
Reinforcement learning rTMS for depression treatment
Reinforcement learning rTMS for depression: a new npj Digital Medicine study tests protocol recommendations against clinician choices in 1,609 adults.
Read Article →
10/15/2026
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
What steps is the FDA taking to accelerate rare disease treatments?
The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies.
Explore how this could reshape drug development for underserved patient populations.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy
Read Article →
10/15/2026
Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.
Read Article →